» Articles » PMID: 29600597

MMP7 Cleaves Remyelination-impairing Fibronectin Aggregates and Its Expression is Reduced in Chronic Multiple Sclerosis Lesions

Overview
Journal Glia
Specialty Neurology
Date 2018 Mar 31
PMID 29600597
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Upon demyelination, transient expression of fibronectin precedes successful remyelination. However, in chronic demyelination observed in multiple sclerosis (MS), aggregates of fibronectin persist and contribute to remyelination failure. Accordingly, removing fibronectin (aggregates) would constitute an effective strategy for promoting remyelination. Matrix metalloproteinases (MMPs) are enzymes known to remodel extracellular matrix components, including fibronectin. Here, we examined the ability of MMPs to degrade fibronectin aggregates. Our findings reveal that MMP7 cleaved fibronectin aggregates resulting into a prominent 13 kDa EIIIA (16 kDa EDA)-containing fragment. MMP7 was upregulated during lysolecithin-induced demyelination, indicating its potential for endogenous fibronectin clearance. In contrast, the expression of proMMP7 was substantially decreased in chronic active and inactive MS lesions compared with control white matter and remyelinated MS lesions. Microglia and macrophages were major cellular sources of proMMP7 and IL-4-activated, but not IFNγ+LPS-activated, microglia and macrophages secreted significant levels of proMMP7. Also, conditioned medium of IL-4-activated macrophages most efficiently cleaved fibronectin aggregates upon MMP-activating conditions. Yet, coatings of MMP7-cleaved fibronectin aggregate fragments inhibited oligodendrocyte maturation, indicating that further degradation and/or clearance by phagocytosis is essential. These findings suggest that MMP7 cleaves fibronectin aggregates, while reduced (pro)MMP7 levels in MS lesions contribute to their persistent presence. Therefore, upregulating MMP7 levels may be key to remove remyelination-impairing fibronectin aggregates in MS lesions.

Citing Articles

Astrocytic TIMP-1 regulates production of Anastellin, an inhibitor of oligodendrocyte differentiation and FTY720 responses.

Sutter P, Willis C, Menoret A, Nicaise A, Sacino A, Sikkema A Proc Natl Acad Sci U S A. 2024; 121(5):e2306816121.

PMID: 38266047 PMC: 10835138. DOI: 10.1073/pnas.2306816121.


The role of fibronectin in multiple sclerosis and the effect of drug delivery across the blood-brain barrier.

Wei S, Chen L, Yang F, Wang S, Wang P Neural Regen Res. 2023; 18(10):2147-2155.

PMID: 37056122 PMC: 10328269. DOI: 10.4103/1673-5374.369102.


Poly-L-ornithine blocks the inhibitory effects of fibronectin on oligodendrocyte differentiation and promotes myelin repair.

Xiong Y, Soomro S, Huang Z, Yu P, Ping J, Fu H Neural Regen Res. 2022; 18(4):832-839.

PMID: 36204851 PMC: 9700116. DOI: 10.4103/1673-5374.353493.


The molecular regulation of oligodendrocyte development and CNS myelination by ECM proteins.

Yamada M, Iwase M, Sasaki B, Suzuki N Front Cell Dev Biol. 2022; 10:952135.

PMID: 36147746 PMC: 9488109. DOI: 10.3389/fcell.2022.952135.


Targeting Fibronectin to Overcome Remyelination Failure in Multiple Sclerosis: The Need for Brain- and Lesion-Targeted Drug Delivery.

van Schaik P, Zuhorn I, Baron W Int J Mol Sci. 2022; 23(15).

PMID: 35955549 PMC: 9368816. DOI: 10.3390/ijms23158418.


References
1.
Larsen P, Yong V . The expression of matrix metalloproteinase-12 by oligodendrocytes regulates their maturation and morphological differentiation. J Neurosci. 2004; 24(35):7597-603. PMC: 6729624. DOI: 10.1523/JNEUROSCI.2092-04.2004. View

2.
Lehnardt S, Massillon L, Follett P, Jensen F, Ratan R, Rosenberg P . Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci U S A. 2003; 100(14):8514-9. PMC: 166260. DOI: 10.1073/pnas.1432609100. View

3.
Franklin R, ffrench-Constant C . Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci. 2008; 9(11):839-55. DOI: 10.1038/nrn2480. View

4.
Imai K, Yokohama Y, Nakanishi I, Ohuchi E, Fujii Y, Nakai N . Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J Biol Chem. 1995; 270(12):6691-7. DOI: 10.1074/jbc.270.12.6691. View

5.
Nair A, Frederick T, Miller S . Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci. 2008; 65(17):2702-20. PMC: 2858316. DOI: 10.1007/s00018-008-8059-5. View